Roundtable: Drug Pricing and Patient Cost
![](https://i0.wp.com/treehillpartners.com/wp-content/uploads/2024/03/Roundtable-Biospace-episode-1.jpg?fit=1000%2C667&ssl=1)
Treehill CEO Ali Pashazadeh in Biospace Roundtable The Gap Is Where The Pain Is: Drug Pricing and Patient Cost Podcast Episode 1 When it comes to drug pricing, there have been (and are) bad actors in the industry, but the conversation usually ends there. Five KOLs from different parts of the industry came together to […]
Interview: Treehill Partners’ Ali Pashazadeh on How to Improve Clinical Trial Design
![](https://i0.wp.com/treehillpartners.com/wp-content/uploads/2023/11/Treehill-Partners-_-Biospace-article-Ali-Pashazadeh-clinical-trials-2023-11-22.jpg?fit=1000%2C563&ssl=1)
BioSpace Article – Published: Nov 22, 2023 By Nadia Bey From Ali Pashazadeh’s perspective, many trials fail because of how they are designed. And as the CEO of financial advisory firm Treehill Partners, he has a plan to solve that. Treehill announced in October that it would provide a tailored service to biopharma companies to help them optimize […]
Fosun Pharma USA and Treehill Partners launch joint efforts for capital investments in biopharma space
![](https://i0.wp.com/treehillpartners.com/wp-content/uploads/2023/11/2023-11-20-Fosun-Treehill.png?fit=605%2C385&ssl=1)
NEW YORK, NY & LONDON – Fosun Pharma USA and Treehill Partners (Treehill) announce the formation of a jointly operating vehicle for investment in clinical-stage assets, further solidifying the relationship between the two companies The newly established business will be looking for high-quality, mid to late-stage assets clinically focused on the United States market. There will also be a […]
Treehill Partners launches novel service aimed at optimizing the biotech drug development process and fostering closer collaboration between key stakeholders
![](https://i0.wp.com/treehillpartners.com/wp-content/uploads/2023/10/Treehill-launches-new-service-e1700728015886.jpg?fit=748%2C406&ssl=1)
The service has been developed to meet headwinds faced by the biotech sector, further exacerbated by a challenging financing and licensing environment London, UK, October 17, 2023 – Treehill Partners, the global healthcare strategic and transaction advisory firm with expertise in drug development and operational restructuring, today announces the full commercial launch of a novel […]
Korean Biotech on the Global Stage (Webinar Syneos Health / Treehill Partners)
![](https://i0.wp.com/treehillpartners.com/wp-content/uploads/2023/10/Korean-Biotech-on-Global-Stage.jpg?fit=1000%2C642&ssl=1)
Syneos One and Treehill Partners discuss how Korean biotech companies can optimize for the realities of today, highlighting alternate pathways to global markets and critical success factors. In this video:Lee Taurman, EVP, Global Head of Syneos One, Syneos HealthAli Pashazadeh, Founder & CEO, Treehill PartnersMax Baumann, Co-Founder & Partner, Treehill Partners Link to Video | […]
Biotech Value Creation (Podcast Syneos Health / Treehill Partners)
![](https://i0.wp.com/treehillpartners.com/wp-content/uploads/2023/10/Biotech-value-creation.jpg?fit=1000%2C667&ssl=1)
The game continues to change in biotech as continued macroeconomic uncertainty has far reaching implications for the future of the biopharma ecosystem. Biotechs can no longer operate toward the single goal of being acquired by, or of licensing their assets to, large pharma—and players may need to develop products further than in the past, and […]
New Opportunities for Value Creation: How Biotechs Can Succeed in an Increasingly Competitive Market (Webinar Syneos Health / Treehill Partners)
![](https://i0.wp.com/treehillpartners.com/wp-content/uploads/2023/09/Syneos-1-scaled.jpg?fit=2560%2C1440&ssl=1)
The game has changed in biotech. Continued macroeconomic uncertainty has far reaching implications for the biopharma ecosystem. Access to capital remains low across the industry, and a successful deal with large pharma has become less likely for many. Companies who earlier would have been sellers, may now be progressing development through registrational studies—or all the […]
Illiquid Gold: Creative Dealmaking in Biotech (Webinar Evaluate / Treehill Partners)
![](https://i0.wp.com/treehillpartners.com/wp-content/uploads/2022/11/Evaluate.jpg?fit=1060%2C565&ssl=1)
Evaluate and Treehill Partners discuss the state of play and look for smart ways to get investment and deals moving as we head into 2023. Cem Baydar and Paul Verdin from Evaluate are joined by Ali Pashazadeh, Max Baumann, and Mark Mayhew from Treehill Partners to discuss the latest dealmaking data, the pipeline pitfalls to […]
Innovation Potential in Mental Health
![Foggy-Brain-Double-Exposure](https://i0.wp.com/treehillpartners.com/wp-content/uploads/2022/04/Foggy-Brain-Double-Exposure.webp?fit=1280%2C700&ssl=1)
Rising awareness and emergence of differentiated solutions for multiple psychiatric and mental health conditions is an ongoing theme of innovation in pharma but also adjacent and “convergence” fields in healthcare. Increasing incidence, certainly exacerbated by lockdowns and other measures implemented to curtail the spread of COVID-19, and the significant lack of innovation in the past represent the key ingredients for a resurgence, which is currently emerging.
The Evolving Digital Health Landscape
![Digital-Health-Doctor](https://i0.wp.com/treehillpartners.com/wp-content/uploads/2022/04/Digital-Health-Doctor.webp?fit=1280%2C700&ssl=1)
Capital allocation towards innovative health-tech solutions has fuelled an increase in adoption of digital technologies. We outline a few current themes and future trends in the area.